Literature DB >> 8414015

Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.

M C Kurth1, J W Tetrud, C M Tanner, I Irwin, G T Stebbins, C G Goetz, J W Langston.   

Abstract

Ten patients with Parkinson's disease suffering severe motor fluctuations completed a double-blind, placebo-controlled, crossover trial of duodenal infusion of levodopa/carbidopa to determine if this technique improved the duration of functional time by reducing plasma levodopa level variability. With infusion, seven patients experienced increased functional "on" hours and decreased number of "off" episodes; however, two patients were slightly worse and one patient experienced no benefit. All 10 patients had significantly decreased variability in levodopa levels permitting better titration of levodopa dosage to individual requirements. Five patients continued to use infusion 12 to 20 months after completion of this study. Selected patients with Parkinson's disease who experience severe motor fluctuations may benefit from duodenal infusion with an improved and prolonged response to medication.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8414015     DOI: 10.1212/wnl.43.9.1698

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

1.  Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease.

Authors:  O K Sujith; Carol Lane
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

2.  Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.

Authors:  Maurizio Zibetti; Aristide Merola; Valeria Ricchi; Alice Marchisio; Carlo Alberto Artusi; Laura Rizzi; Elisa Montanaro; Dario Reggio; Claudio De Angelis; Mario Rizzone; Leonardo Lopiano
Journal:  J Neurol       Date:  2012-07-08       Impact factor: 4.849

3.  Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.

Authors:  Mariachiara Sensi; F Preda; L Trevisani; E Contini; D Gragnaniello; J G Capone; E Sette; N Golfre-Andreasi; V Tugnoli; M R Tola; R Quatrale
Journal:  J Neural Transm (Vienna)       Date:  2014-01-08       Impact factor: 3.575

Review 4.  Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.

Authors:  P Jenner; A C McCreary; D K A Scheller
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 5.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 6.  Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.

Authors:  M C Kurth
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

7.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

8.  Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care.

Authors:  A Antonini; P Odin; L Opiano; V Tomantschger; C Pacchetti; B Pickut; U E Gasser; D Calandrella; F Mancini; M Zibetti; B Minafra; I Bertaina; P De Deyn; C Cras; E Wolf; S Spielberger; W Poewe
Journal:  J Neural Transm (Vienna)       Date:  2013-04-18       Impact factor: 3.575

9.  Is there a difference in gastric emptying between Parkinson's disease patients under long-term L-dopa therapy with and without motor fluctuations? An analysis using the 13C-acetate breath test.

Authors:  Yuji Tanaka; Tomohiro Kato; Hiroshi Nishida; Hiroshi Araki; Masahiko Murase; Masahito Nagaki; Hisataka Moriwaki; Takashi Inuzuka
Journal:  J Neurol       Date:  2009-12       Impact factor: 4.849

10.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.